Teva has agreed to pay a whopping $1.2 billion to settle a US lawsuit claiming its subsidiary Cephalon paid to hold up generic competition to its narcolepsy therapy Provigil. In a statement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback